Indian Teneligliptin Saga: Brands Bazaar, Surging Volumes
Executive Summary
More than two dozen brands, a sharp spurt in sales volumes and a price decline of over 60% currently appear to characterize the market for the type 2 diabetes therapy teneligliptin in India. And market watchers claim that teneligliptin volumes in the country have surpassed the combined numbers of some of the more established gliptins, including vildagliptin and sitagliptin.
You may also be interested in...
Competition Piles Up: 100 Teneligliptin Brands Now In India
A hundred teneligliptin brands (including the combination) are said to now jostle for space in the competitive Indian DPP-4 (dipeptidyl peptidase-4) inhibitor market. An uptick in volumes and a significant decline in the prices of teneligliptin probably mean that Merck’s Januvia and Novartis’ Galvus will need to keep a sharp eye on the molecule in the diabetes segment in India.
BI-Lupin Deal To Up The Heat In Indian DPP-4 Market
Innovator firms continue to tap into the marketing muscle of domestic companies as they vie for a bigger share of India's highly competitive dipeptidyl peptidase-4 (DPP-4) inhibitor market.
Permanent Indian Bar Against Glenmark’s Sitagliptin Copies
An Indian court has permanently enjoined Glenmark from making and selling its generic version of Merck’s diabetes therapies Januvia and Janumet after the Indian firm was found to have infringed the sitagliptin patent.